TIVIC HE.S. NEW DL -,0001 Aktie

Tivic Health Systems received a notification from NASDAQ because the closing price of its common stock was below $1.00 for at least 30 consecutive trading days. The stock currently trades at $0.92; the company has until September 15, 2026 to raise the price to $1.00 or more for ten consecutive trading days, otherwise delisting proceedings—possibly with an extension—may follow. The shares will continue to trade on the Nasdaq Capital Market for now, and the company is evaluating options to cure the deficiency. » More on de.investing.com

Tivic Health Systems' subsidiary Velocity Bioworks has signed three leases in San Antonio for production and office space, including new headquarters office space. One of the leases includes an exclusive purchase option for the building and land for $12.5 million; combined base rents over the terms amount to several million dollars. At the same time, the company reports a 200-fold increase in production of its drug candidate Entolimod in a 50-liter volume (about 1.3 million doses) and confirms compliance with relevant purity and efficacy standards. Despite a sharply fallen share price, analyses indicate a strong liquidity position, with cash and liquid assets exceeding short-term liabilities. » More on de.investing.com

In a joint study with the Feinstein Institutes, Tivic Health identified optimal, individually adjustable stimulation frequencies for its ncVNS technology; personalized frequencies increased heart rate variability by 46% and were 8.9 times more effective than standardized settings. Researchers also found that electrode placement strongly influences effectiveness and that four-minute sessions produced better results than 20-minute treatments. The company is advancing its bioelectronic program, recently reported declining revenues, is working on patent and IND applications, and is preparing for its quarterly report. » More on de.investing.com